All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Priority Review to Ruxolitinib in Polycythemia Vera

August 5th 2014

The FDA has assigned a priority review designation to the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

Deadline Set for ICD-10 Changeover

August 4th 2014

The US Department of Health and Human Services has finalized Oct. 1, 2015, as the new compliance date for providers and payers to transition to ICD-10.

Carfilzomib Combination Effective for Relapsed Myeloma

August 4th 2014

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma

CMS, MedPAC Propose Site-Neutral Payment Systems

July 31st 2014

A new health policy brief issued by Health Affairs and the Robert Wood Johnson Foundation explains the origin of these differential payments and the debate over approaches that have been proposed for developing so called "site neutral" payments.

More Front-End Billing Staff Trained in Financial Counseling

July 29th 2014

Having financial counselors on staff is becoming a new reality for oncology practices as patients are responsible for out-of-pocket costs and more are participating in health insurance exchanges, says an article in Healthcare Finance News.

Promising Findings for Afatinib-Cetuximab Combo in Previously Treated EGFR-Mutant Lung Cancer

July 29th 2014

Results of an early-phase study have shown the combination of afatinib (Gilotrif) and cetuximab (Erbitux) has utility in EGFR-mutant lung cancer patients who have developed resistance to gefitinib (Tarceva) and erlotinib (Iressa).

FDA Expands Ibrutinib's CLL Approval

July 28th 2014

The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy and harbor a 17p deletion.

Sorafenib Does Not Improve PFS in Phase III Breast Cancer Study

July 25th 2014

A phase III trial analyzing sorafenib for the treatment of patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival.

Percentage of Physicians Using EHRs for Electronic Prescribing Rises from 7% to 70% in 6 Year Period

July 23rd 2014

It looks like e-prescribing through the use of electronic health records (EHRs) is here to stay according to findings from the July 2014 "ONC Data Brief," issued by The Office of the National Coordinator for Health Information Technology.

FDA Approves Idelalisib for CLL, SLL, and Follicular Lymphoma

July 23rd 2014

The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.

Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study

July 23rd 2014

Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab

Bevacizumab Receives Priority Review in Ovarian Cancer

July 22nd 2014

The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer

July 21st 2014

The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.

Specialists Balk at Recertification Rules

July 21st 2014

Many specialists are balking at what they say are onerous new rules to get recertified, warning the demands will force some physicians out of practice at a time when the nation faces a shortage.

Dabrafenib/Trametinib Extends OS Versus Vemurafenib in Phase III Melanoma Trial

July 18th 2014

A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis

Gel, Oral Routes Equivalent for Tamoxifen in DCIS

July 18th 2014

A gel formulation of tamoxifen is equally as effective with fewer side effects when compared with oral tamoxifen in women with ductal carcinoma in situ.

Lanreotide Improves PFS in Patients With Neuroendocrine Tumors

July 17th 2014

The somatostatin analog lanreotide (Somatuline Depot) significantly prolonged progression-free survival (PFS) compared with placebo for patients with metastatic gastroenteropancreatic neuroendocrine tumors.

Memorial Sloan Kettering Ranks First in the Nation for Cancer Care

July 16th 2014

Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation.

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer

July 15th 2014

The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Cancer Patients' Use of Electronic Portals Rising

July 15th 2014

As the use of electronic patient portals grows, a new study examines the use of these portals by cancer patients, extending the doctor-patient relationship to new boundaries.